熱門資訊> 正文

靶向基因组学，OraSure在家庭乳糜泻基因检测协议

2025-05-14 22:03

奧瑞許科技(OSUR) 0

Targeted Genomics LLC announced a commercial collaboration with OraSure Technologies (NASDAQ:OSUR), the maker of ORAcollect·Dx, a saliva collection device approved for general over-the-counter use.
This partnership aims to broaden consumer access to at-home genetic testing for celiac disease.

More on OraSure Technologies

OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript
OraSure Technologies: Historically Cheap
OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript
Orasure technologies outlines Q2 2025 revenue guidance of $28.5M-$32.5M amid new product launches and customer expansions
OraSure Technologies Q1 2025 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。